Nefopam Hydrochloride

盐酸奈福泮

Report date: 2023/01/13 20:00:32
NME

Base Information

Drug NameNefopam Hydrochloride
Drug Alias Name盐酸萘福泮nefopamumnefopam奈福泮Ajan +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdrenergic receptors agonistsMuscarinic acetylcholine receptor M3 antagonists
TargetsAdrenergic receptorsMuscarinic acetylcholine receptor M3
Therapy Area/IndicationsSedationPain, ProceduralCancer Pain +[8] 
Global Approved IndicationsCancer PainPainPain, Postoperative
Approved Indications in ChinaCancer PainPainPain, Postoperative
Original Approved Country/TerritoryMainland China
Original Approved DateN/A
Country/TerritoryCanadaEgyptUnited Kingdom +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesCosci Med-Tech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCairo UniversityJordan University Of Science And TechnologyShenyang Dong'Ang Pharmaceutical Co Ltd
Inactive CompaniesGalen LtdScarx Corp
Active IndicationsSedationPain, ProceduralCancer Pain +[7] 
Inactive IndicationsCicatrix

Other Information

ATC CodeN02BG06
Related LinksWikipediaKEGG